Tumor mutational burden (TMB) and co-existing actionable mutations in biliary tract cancers (BTC).

被引：9

作者：

Jain, Apurva

Shroff, Rachna T.

Zuo, Mingxin

Weatherly, Jacqueline

Meric-Bernstam, Funda

Isaacs, Randi

Ali, Siraj Mahamed

Bekaii-Saab, Tanios S.

Javle, Milind M.

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, GI Med Oncol Dept, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut Phase I Program, Houston, TX 77030 USA

[5] Novartis Inst Biomed Res, Cambridge, MA USA

[6] Fdn Med Inc, Cambridge, MA USA

[7] Mayo Clin, Canc Ctr, Phoenix, AZ USA

[8] Univ Texas MD Anderson Canc Ctr, Gastrointestinal Med Oncol, Houston, TX 77030 USA

来源：

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.4086

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4086

引用

页数：5